https://www.thebodypro.com/category/hiv-treatment-strategies

HIV Treatment Strategies

The Latest

patient with COVID-19
Conference Coverage

HIV Status Does Not Affect COVID-19 Hospitalization, Short-Term Outcomes in Connecticut Hospital

The findings add to a growing body of research showing that it’s other co-morbidities, not HIV, that lead to worse health outcomes from COVID-19—at least among individuals who are on stable antiretroviral therapy.

By Larry Buhl
COVID-19 mask profile
News

This Week in HIV Research: The Real-World Effects of COVID-19

Oct. 22, 2020: Impact of COVID-19 shutdowns on HIV viral suppression; unsuppressed HIV viral load despite no treatment failure; point-of-care rapid testing vs. lab testing; it's not about "what," it's about "when."

By Barbara Jungwirth and Myles Helfand
sizes and shapes
News

This Week in HIV Research: Many Sizes Fit Many People

Oct. 15, 2020: Adherence barriers among Latinx MSM; Atlanta's Ending the HIV Epidemic priorities; Ryan White HIV service coordination; PrEP, white coat dosing, and drug resistance.

By Barbara Jungwirth and Myles Helfand
reflect rethink revise
News

This Week in HIV Research: Revisiting Our Needs

Oct. 8, 2020: HPV-related cancer risk among women living with HIV; the interplay between HIV, HBV, and liver disease; Framingham vs. other tools to gauge statin value; integrase inhibitors, weight gain, and menopause.

By Barbara Jungwirth and Myles Helfand
monoclonal antibodies
Interviews

Are Monoclonal Antibodies the Future of COVID-19 Treatment?

Infectious-diseases researcher David Wohl, M.D., talks about a major COVID-19 treatment trial in the works—and how it relates to our efforts against HIV.

By Terri Wilder, M.S.W.
BLM health care
News

This Week in HIV Research: The Long Road to Racial Health Justice

Sept. 24, 2020: HIV adherence cohorts usually fail to reflect the diversity of the epidemic; HIV thrives in deprived neighborhoods; rethinking barriers to rapid HIV treatment initiation; long-term adverse events on INSTIs vs. efavirenz.

By Barbara Jungwirth and Myles Helfand
Juan Berenguer, M.D., Ph.D. and Antonio Urbina, M.D.
Interviews

Immediate HIV Treatment Initiation With Integrase Inhibitors Leads to Large Drop in Secondary HIV Transmission Among MSM

Integrase inhibitors are known to be potent first-line therapy options. Recent research suggests their benefits extend to onward HIV prevention as well.

By Terri Wilder, M.S.W. and Myles Helfand
doctor with trans patient
News

This Week in HIV Research: When Treating Trans Patients, Check Your Priors

Aug. 27, 2020: Traditional CVD risk calculation tools falter for transgender women; switching to B/F/TAF despite NRTI resistance; how tenofovir has altered the HBV landscape; syndemic effects on viral load and blood pressure.

By Barbara Jungwirth and Myles Helfand
brain dissipation
News

This Week in HIV Research: What We Don’t Know Hurts Them

Aug. 20, 2020: HIV knowledge and stigma among health care workers in the southern U.S.; condomless sex vs. HIV risk among MSM; how drug class choice may affect onward transmission risk; STI screening rates among MSM on PrEP.

By Barbara Jungwirth and Myles Helfand
mouth to ear
News

This Week in HIV Research: Why Aren’t We Listening to Ourselves?

Aug. 13, 2020: HCV testing rates among people newly diagnosed with HIV; HCV treatment referrals ammong coinfected people; HIV mortality rates despite free treatment access; mysterious, plummeting CD4 test results.

By Barbara Jungwirth and Myles Helfand